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percent of lung volume) among those with a 
higher amount of potentially recruitable lung, 
but these volumes included 183±482 and 135±434 
ml of gas, respectively, and only 14±32 and 11±35 
g of tissue, respectively, accounting for 1±3 per-
cent and 1±2 percent of the total lung tissue.
Luciano Gattinoni, M.D.
Pietro Caironi, M.D.
Fondazione Istituto di Ricovero e Cura a Carattera Scientifico 
20122 Milan, Italy
gattinon@policlinico.mi.it
V. Marco Ranieri, M.D.
Azienda Ospedaliera San Giovanni Battista-Molinette 
10126 Turin, Italy
Borges JB, Okamoto VN, Matos GF, et al. Reversibility of 
lung collapse and hypoxemia in early acute respiratory distress 
syndrome. Am J Respir Crit Care Med (in press).
Brower RG, Morris A, MacIntyre N, et al. Effects of recruit-
ment maneuvers in patients with acute lung injury and acute 
respiratory distress syndrome ventilated with high positive end-
expiratory pressure. Crit Care Med 2003;31:2592-7. [Erratum, 
Crit Care Med 2004;32:907.]
D’Angelo E, Calderini E, Robatto FM, Puccio P, Milic-Emili J. 
Lung and chest wall mechanics in patients with acquired immu-
nodeficiency syndrome and severe Pneumocystis carinii pneu-
monia. Eur Respir J 1997;10:2343-50.
Quintel M, Pelosi P, Caironi P, et al. An increase of abdomi-
nal pressure increases pulmonary edema in oleic acid-induced 
lung injury. Am J Respir Crit Care Med 2004;169:534-41.
The National Heart, Lung, and Blood Institute Acute Respi-
ratory Distress Syndrome (ARDS) Clinical Trials Network. Com-
parison of two fluid-management strategies in acute lung injury. 
N Engl J Med 2006;354:2564-75
1.
2.
3.
4.
5.
Hepatitis B Virus with Primary Resistance to Adefovir
To the Editor: Schildgen et al. (April 27 issue)1 
describe the results of tenofovir treatment in 
three patients infected with adefovir-resistant vari-
ant hepatitis B virus (HBV) that had a valine at 
position 233 of the reverse-transcriptase domain 
instead of isoleucine (rtI233V). We recently pub-
lished the results of two trials in which entecavir 
demonstrated superiority over lamivudine in pa-
tients with chronic hepatitis B that was positive 
for antibody against hepatitis B e antigen (HBeAg)2 
and in patients with HBeAg-negative chronic hep-
atitis B.3
Four of the patients with HBeAg-positive chron-
ic hepatitis B and four of those with HBeAg-
H
B
V
 D
N
A
 (c
op
ie
s/
m
l)
1011
1012
1010
109
107
106
104
103
102
10
108
105
0
0 24 36 48
Week
Patient 1, HBeAg-positive
Patient 2, HBeAg-positive
Patient 3, HBeAg-positive
Patient 4, HBeAg-positive
Patient 5, HBeAg-negative
Patient 6, HBeAg-negative
Patient 7, HBeAg-negative
Patient 8, HBeAg-negative
1013
Figure 1. Decrease in HBV DNA Levels during 48 Weeks of Entecavir Therapy in Eight Patients with an rtI233V 
Mutation in HBV Conferring Primary Resistance to Adefovir.
The limit of detection of the polymerase-chain-reaction assay was 300 copies per milliliter. Data on the HBV DNA 
burden at 24 weeks were not available for Patient 4.
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negative chronic hepatitis B were infected with a 
strain that had the rtI233V mutation and received 
entecavir therapy. After 48 weeks, all six patients 
with paired liver-biopsy specimens that could be 
evaluated had histologic improvement, and two 
of the four HBeAg-positive patients had serocon-
version.
Seven of the eight patients had undetectable 
viral loads (<300 copies of HBV DNA per milliliter) 
by week 36, and the mean decrease from base-
line was 6.75 log (on a base-10 scale) copies per 
milliliter in the HBeAg-positive group and 5.11 
log copies per milliliter in the HBeAg-negative 
group (Fig. 1). We tested the in vitro susceptibil-
ity to entecavir of one HBV isolate with the rtI233V 
(and V191I) mutation from our viral archive and 
found a median effective concentration of 1.4 nM, 
as compared with 4 nM for wild-type virus.
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The authors reply: Chang and Lai describe 
eight patients infected with an HBV variant carry-
ing the novel rtI233V mutation we recently iden-
tified in three German patients. It causes primary 
resistance to adefovir, and it was also recently 
described in one Australian patient in whom adef-
ovir therapy failed.1
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Chang and Lai report that their patients were 
very efficiently treated with entecavir. We greatly 
appreciate their rapid comments for two reasons. 
First, their data, in agreement with ours, indicate 
that the rtI233V mutation occurs in approximate-
ly 2 percent of all patients with chronic hepatitis B 
(8 of 434 patients). Thus, our finding was not an 
isolated observation. It remains surprising that 
the mutation was not detected in earlier studies 
of adefovir.2,3
Second, the observations by Chang and Lai 
show entecavir to be a highly efficient therapy op-
tion for patients with the rtI233V mutation who 
have no response to adefovir, since tenofovir, 
which is what we used in our study, is still not 
licensed for HBV therapy. Since the receipt of 
lamivudine therapy for more than 12 weeks was 
an exclusion criterion in their studies, it is very 
likely that their patients were sensitive to lamiv-
udine. Thus, it remains unknown how useful ente-
cavir would be in patients with lamivudine-resis-
tant rtI233V mutations. In our study, two patients 
with a response to tenofovir were resistant to 
lamivudine.
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